Onyx to Invest in Continuous Flow Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Onyx to Invest in Continuous Flow Technology


Onyx Scientific, a UK-based CRO, has announced plans to invest in continuous flow manufacturing to allow its customers to explore alternatives during product research and development programs. The company intends to adopt a more novel approach to manufacturing API in a bid to overcome the often time-consuming and costly process of batch manufacturing.

“The move to continuous flow manufacturing has been seen by a handful of companies in the sector to date so we feel that we are very much at the forefront of technological advances when it comes to the development and production of API,” commented Denise Bowser, commercial director at Onyx Scientific, in a press statement. “For us, it makes better use of our space, gives us a quicker output and provides greater flexibility in the manufacturing of compounds as well as delivering considerable cost savings, which we can pass onto clients.”

Onyx Scientific is also strengthening its GMP capability following increased market demand for its GMP API manufacturing services. The decision was made to satisfy the market demand in the company’s GMP capability from big pharma companies, biotechs, universities and major charities involved in drug development. Onyx Scientific reported a 45% uplift in solid-state chemistry related revenues last year, which was driven by early stage campaigns.

With MHRA and FDA facilities in the UK and India, Onyx Scientific assists companies from medicinal chemistry and preclinical through Phase I–III, scaling-up to API production. It also recently enhanced its presence in the US by adding local representation to support west coast clients.

Source: Onyx Scientific 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here